Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Inc.

In a dramatic turn of events, Skye Bioscience, Inc. finds itself at the center of a class action lawsuit, accused of misleading investors about the...

Market Cap	$46.79M	P/E Ratio	N/A
52W High	$5.75	52W Low	$1.10
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	N/A	52W Position	-0.2%
Overall Score	36	Value Score	60
Quality Score	23	Technical Score	25

EPS Current Est	$-1.42	EPS Next Est	$-1.11
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$1.09	-5.22%	362.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$1.09	-5.2%	362.67K
3
4
5
6

SKYE

SKYE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Skye Bioscience Inc. Data in Excel

Get Skye Bioscience Inc. Data in Excel